Menu
Search
|

Menu

Close
X

Celsion Corp CLSN.OQ (NASDAQ Stock Exchange Capital Market)

2.13 USD
-0.07 (-3.18%)
As of Feb 20
chart
Previous Close 2.20
Open 2.17
Volume 21,599
3m Avg Volume 325,273
Today’s High 2.21
Today’s Low 2.12
52 Week High 6.06
52 Week Low 1.25
Shares Outstanding (mil) 8.35
Market Capitalization (mil) 27.98
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
1.00 Mean rating from 2 analysts

KEY STATS

Revenue (mm, USD)
FY17
0
FY16
0
FY15
0
EPS (USD)
FY17
-3.197
FY16
-11.928
FY15
-14.610
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
32.90
Price to Sales (TTM)
vs sector
55.95
5.77
Price to Book (MRQ)
vs sector
2.98
5.41
Price to Cash Flow (TTM)
vs sector
--
23.42
Total Debt to Equity (MRQ)
vs sector
0.00
16.52
LT Debt to Equity (MRQ)
vs sector
0.00
12.22
Return on Investment (TTM)
vs sector
-78.33
14.43
Return on Equity (TTM)
vs sector
-191.72
16.13

EXECUTIVE LEADERSHIP

Jeffrey Church
Chief Financial Officer, Senior Vice President, Corporate Secretary, IR Contact Officer, Since 2014
Salary: $293,485.00
Bonus: $71,352.00
Khursheed Anwer
Executive Vice President, Chief Scientific Officer - Nucleic Acid Therapy, Since 2014
Salary: $154,731.00
Bonus: $55,964.00
Nicholas Borys
Senior Vice President and Chief Medical Officer, Since 2014
Salary: $346,876.00
Bonus: $90,590.00
Michael Tardugno
Executive Chairman of the Board, President, Chief Executive Officer, Since 2014
Salary: $462,422.00
Bonus: $298,803.00
Donald Braun
Independent Director, Since 2015
Salary: --
Bonus: --

COMPANY PROFILE

Sector: Healthcare
Industry: Biotechnology & Medical Research
Address:

997 Lenox Dr Ste 100
LAWRENCE TOWNSHIP   NJ   08648-2317

Phone: +1609.8969100
Site: celsion.com/

Celsion Corporation is an oncology drug development company. The Company's product candidate is ThermoDox, a heat-activated liposomal encapsulation of doxorubicin, which is in Phase III clinical trial for treatment of primary liver cancer (the OPTIMA Study) and a Phase II clinical trial for treatment of recurrent chest wall breast cancer (the DIGNITY Study). Its pipeline also includes GEN-1, a deoxyribonucleic acid (DNA) mediated immunotherapy for the localized treatment of ovarian and brain cancers. It has over three platform technologies for the development of treatments for those suffering with difficult-to-treat forms of cancer, including Lysolipid Thermally Sensitive Liposomes, a heat sensitive liposomal based dosage form that targets disease with known therapeutics in the presence of mild heat; TheraPlas, a nucleic acid-based treatment for local transfection of therapeutic plasmids, and TheraSilence, a systemic dosage form for lung directed anti-cancer ribonucleic acid (RNA).

SPONSORED STORIES